NCT03368963 - TAS102 in Combination With NAL-IRI in Advanced GI Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

June 28, 2025

Study Completion Date

November 28, 2025

Conditions

Colorectal AdenocarcinomaGastric AdenocarcinomaMetastatic Pancreatic AdenocarcinomaNon-Resectable CholangiocarcinomaStage IV Colorectal CancerStage IV Gastric CancerStage IV Pancreatic CancerStage IVA Colorectal CancerStage IVB Colorectal CancerStage III Colorectal CancerStage III Gastric CancerStage III Pancreatic CancerUnresectable Digestive System AdenocarcinomaUnresectable Pancreatic Carcinoma

Interventions

DRUG

Nanoliposomal Irinotecan

Given IV

DRUG

Trifluridine and Tipiracil Hydrochloride

Given PO

Trial Locations (3)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta